Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

BACKGROUND: Immune-checkpoint inhibitors plus chemotherapy are emerging as effective first-line treatment in advanced non-small-cell lung carcinoma (NSCLC), but little is known about the magnitude of benefits and potential clinical predictors. METHODS: We performed a meta-analysis of randomized tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yixin, Chen, Chen, Zhang, Xuanye, Fu, Sha, Xue, Cong, Ma, Yuxiang, Fang, Wenfeng, Yang, Yunpeng, Hou, Xue, Huang, Yan, Zhao, Hongyun, Hong, Shaodong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303974/
https://www.ncbi.nlm.nih.gov/pubmed/30577837
http://dx.doi.org/10.1186/s40425-018-0477-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303974/
https://www.ncbi.nlm.nih.gov/pubmed/30577837
http://dx.doi.org/10.1186/s40425-018-0477-9

Ejemplares similares